AUR-AD9F-TTM1-A-1-1-R-A542-39
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.540
- BILE_ACID_METABOLISM+0.490
- COAGULATION+0.470
- HYPOXIA+0.460
- FATTY_ACID_METABOLISM+0.440
- OXIDATIVE_PHOSPHORYLATION+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- PEROXISOME+0.380
- ADIPOGENESIS+0.370
- GLYCOLYSIS+0.370
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.310
- INTERFERON_GAMMA_RESPONSE-0.260
- ALLOGRAFT_REJECTION-0.220
- INTERFERON_ALPHA_RESPONSE-0.190
- HEDGEHOG_SIGNALING-0.130
- APICAL_JUNCTION-0.110
- TGF_BETA_SIGNALING-0.090
- INFLAMMATORY_RESPONSE-0.080
- KRAS_SIGNALING_DN-0.060
- APICAL_SURFACE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-73-4676-01A-01R-1755-07 | — | cohortA1 | 0.846 |
| 2 | f34c57ee-92a6-4e3b-acde-7fd631c42f87 | — | — | 0.839 |
| 3 | SRR6013485 | — | cohortA4 | 0.810 |
| 4 | PLCPRF5_LIVER | HCC | — | 0.808 |
| 5 | AUR-AERY-TTM1-A-1-1-R-A742-41 | — | C | 0.796 |
| 6 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.785 |
| 7 | SRR1313110 | — | C | 0.777 |
| 8 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.772 |
| 9 | aMVAC.P_015_TURBT_S235 | — | — | 0.771 |
| 10 | SNU878_LIVER | HCC | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.540 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.490 | Inavolisib | — uncovered |
| COAGULATION | 0.470 | Binimetinib | — uncovered |
| HYPOXIA | 0.460 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| PEROXISOME | 0.380 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |